Noblett Karen 4

Accession 0001562180-23-000872

CIK 0001603756other

View on SEC.gov Company Profile

Filed

Feb 1, 7:00 PM ET

Accepted

Feb 2, 8:06 PM ET

Size

25.7 KB

Accession

0001562180-23-000872

Insider Transaction Report

Form 4

Period: 2023-01-31

Axonics, Inc.AXNX

Noblett Karen

Chief Medical Officer

Transactions

Award
Performance-Based Restricted Stock Units
2023-01-31+15,000→ 15,000 total
From: 2024-01-31→ Common Stock (15,000 underlying)
Award
Performance-Based Restricted Stock Units
2023-01-31+5,000→ 5,000 total
From: 2025-01-31→ Common Stock (5,000 underlying)
Sale
Common Stock
2023-01-31$61.17/sh−2,167$132,554→ 44,682 total
Exercise/Conversion
Performance-Based Restricted Stock Units
2023-01-31−4,250→ 0 total
From: 2023-01-31→ Common Stock (4,250 underlying)
Exercise/Conversion
Common Stock
2023-01-31+10,250→ 46,849 total
Sale
Common Stock
2023-02-01$61.02/sh−795$48,508→ 42,215 total
Award
Common Stock
2023-01-31+5,000→ 36,599 total
Sale
Common Stock
2023-01-31$61.12/sh−1,536$93,883→ 43,146 total
Sale
Common Stock
2023-02-01$60.43/sh−136$8,219→ 43,010 total
Exercise/Conversion
Performance-Based Restricted Stock Units
2023-01-31−6,000→ 0 total
From: 2023-01-31→ Common Stock (6,000 underlying)

Footnotes (9)

[F1]Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the conversion of the Performance-Based Restricted Stock Units disclosed herein.
[F2]This transaction was executed in multiple trades at prices ranging from $60.78 to $61.595. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
[F3]This transaction was executed in multiple trades at prices ranging from $60.78 to $61.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
[F4]This transaction was executed in multiple trades at prices ranging from $59.85 to $60.845. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
[F5]This transaction was executed in multiple trades at prices ranging from $60.85 to $61.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
[F6]Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2023 and provided the reporting person remains in continuous service through January 31, 2024.
[F7]The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2025, and provided the reporting person remains in continuous service through January 31, 2025.
[F8]Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2022 and provided the reporting person remains in continuous service through January 31, 2023.
[F9]The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2023, and provided the reporting person remains in continuous service through January 31, 2023.

Documents

1 file

4
primarydocument.xmlPrimary
PRIMARY DOCUMENT

Issuer

Axonics, Inc.

CIK 0001603756

→

Entity typeother

Related Parties

filerCIK 0001756240

Filing Metadata

Form type: 4
Filed: Feb 1, 7:00 PM ET
Accepted: Feb 2, 8:06 PM ET
Size: 25.7 KB

View on SEC.gov